nach oben

Erschienen in:

2019 | OriginalPaper | Buchkapitel

Evolution of HCV NS4B Inhibitors

verfasst von : Giuseppe Manfroni, Rolando Cannalire

Erschienen in: HCV: The Journey from Discovery to a Cure

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

NS4B has remained for a long time an undisclosed target within the HCV drug discovery programs. However, impressive drug discovery efforts from 2005 to 2016 led to the identification of different chemical classes targeting NS4B as effective anti-HCV agents, and some of them act by impairing AH2-mediated membranous web formation or RNA-binding property. This book chapter aims to discuss research published on NS4B inhibitors focusing on hit identification and hit-to-lead optimization, also with respect to pharmacokinetic properties and structure-activity relationships raised for the different chemical classes taken into account. To date, the only clinical trial conducted with molecules targeting NS4B was focused on clemizole hydrochloride. However, even if NS4B ligands are not currently used in therapy, they can serve in the near future as new weapons to combat resistance to the current therapy.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments

Nächstes Kapitel The Evolution of Clinical Trials for Hepatitis C

Selby MJ, Choo QL, Berger K et al (1993) Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol 74:1103–1113PubMed

Kim JE, Song WK, Chung KM et al (1999) Subcellular localization of hepatitis C viral proteins in mammalian cells. Arch Virol 144(2):329–343PubMed

Sklan EH, Glenn JS (2006) HCV NS4B: from obscurity to central stage. In: Tan SL (ed) Hepatitis C viruses: genomes and molecular biology. Horizon Bioscience, Norfolk, pp 245–266

Hugle T, Fehrmann F, Bieck E et al (2001) The hepatitis C virus nonstructural protein 4b is an integral endoplasmic reticulum membrane protein. Virology 284:70–81PubMed

Lundin M, Monné M, Widell A et al (2003) Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol 77:5428–5438PubMedPubMedCentral

Elazar M, Liu P, Rice C et al (2004) An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol 78:11393–11400PubMedPubMedCentral

Gouttenoire J, Castet V, Montserret R et al (2009) Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. J Virol 83:6257–6268PubMedPubMedCentral

Gouttenoire J, Montserret R, Kennel A et al (2009) An amphipathic-helix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association. J Virol 83:11378–11384PubMedPubMedCentral

Gouttenoire J, Montserret R, Paul D et al (2014) Aminoterminal amphipathic α-helix AH1 of hepatitis C virus non-structural protein 4B possesses a dual role in RNA replication and virus production. PLoS Pathog 10:e1004501PubMedPubMedCentral

10.

Lundin M, Lindström H, Grönwall C et al (2006) Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. J Gen Virol 87:3263–3272PubMed

11.

Romero-Brey I, Merz A, Chiramel A et al (2012) Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 8:e1003056PubMedPubMedCentral

12.

Einav S, Elazar M, Danieli T et al (2004) A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J Virol 78:11288–11295PubMedPubMedCentral

13.

Thompson AA, Zou A, Yan J et al (2009) Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. Biochemistry 48:906–916PubMed

14.

Einav S, Sklan EH, Moon HM et al (2008) The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology 47:827–835PubMed

15.

Palomares-Jerez MF, Villalaín J (2011) Membrane interaction of segment H1 (NS4B(H1)) from hepatitis C virus non-structural protein 4B. Biochim Biophys Acta 1808:1219–1229PubMed

16.

Guillén J, González-Alvarez A, Villalaín J et al (2010) A membranotropic region in the C-terminal domain of hepatitis C virus protein NS4B interaction with membranes. Biochim Biophys Acta 1798:327–337PubMed

17.

Aligo J, Jia S, Manna D et al (2009) Formation and function of hepatitis C virus replication complexes require residues in the carboxy-terminal domain of NS4B protein. Virology 393:68–83PubMedPubMedCentral

18.

Liefhebber JM, Brandt BW, Broer R et al (2009) Hepatitis C virus NS4B carboxy terminal domain is a membrane binding domain. Virol J 6:62PubMedPubMedCentral

19.

Einav S, Gerber D, Bryson PD et al (2008) Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 26:1019–1027PubMedPubMedCentral

20.

Yu GY, Lee KJ, Gao L et al (2006) Palmitoylation and polymerization of hepatitis C virus NS4B protein. J Virol 80:6013–6023PubMedPubMedCentral

21.

Fogeron ML, Jirasko V, Penzel S et al (2016) Cell-free expression, purification, and membrane reconstitution for NMR studies of the nonstructural protein 4B from hepatitis C virus. J Biomol NMR 65(2):87–98PubMed

22.

Paul D, Madan V, Ramirez O et al (2017) Glycine-zipper motifs in hepatitis C virus nonstructural protein 4B are required for the establishment of viral replication organelles. J Virol doi:https://doi.org/10.1128/JVI.01890-17. JVI.01890

23.

Rai R, Deval J (2001) New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antivir Res 90:93–101

24.

Cho NJ, Dvory-Sobol H, Lee C et al (2010) Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med 2:1–8

25.

Chunduru SK, Benatatos CA, Nits TJ et al (2005) Compounds, compositions, and methods for treatment and prophylaxis of hepatitis viral C infection and associates diseases. WO2005051318

26.

Arico-Muendel C, Zhu Z, Dickson H et al (2015) Encoded library technology screening of hepatitis C virus NS4B yields a small molecule compound series with in vitro replicon activity. Antimicrob Agents Chemother 59:3450–3459PubMedPubMedCentral

27.

Cannalire R, Barreca ML, Manfroni G et al (2016) A journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates. J Med Chem 59:16–41PubMed

28.

Wang Z, Chen X, Wu C et al (2016) Current drug discovery for anti-hepatitis C virus targeting NS4B. Curr Top Med Chem 16(12):1362–1371PubMed

29.

Finkelstein M, Kromer CM, Sweeney SA et al (1960) Some aspects of the pharmacology of clemizole hydrochloride. J Am Pharm Assoc Sci Ed 49:18–22

30.

Einav S, Sobol HD, Gehrig E et al (2010) The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 202:65–74PubMedPubMedCentral

31.

Choong IC, Cory D, Gleen JS et al (2012) Method and composition of treating a Flaviviridae family infection. US/027605A1

32.

Choong IC, Cory D, Gleen JS et al (2010) Method and composition of treating a Flaviviridae family infection. WO2010/107739

33.

Choong IC, Gleen JS, Yang W (2010) Method and composition of treating a Flaviviridae family infection. WO2010/107742

34.

Gleen JS, Yang W, Choong IC (2012) Method and composition of treating a Flaviviridae family infection. US2012/0148534

35.

https://clinicaltrials.gov/ct2/show/NCT00945880?term=clemizole&rank=1. Accessed 19 Jan 2018

36.

Chunduru SK, Benatatos CA, Nits TJ, et al (2007) Compounds, compositions, and methods for treatment and prophylaxis of hepatitis viral C infection and associates diseases. US200770264920A1

37.

Bryson PD, Cho NJ, Einav S et al (2010) A small molecule inhibits HCV replication and alters NS4B’s subcellular distribution. Antivir Res 87:1–8PubMed

38.

Choi M, Lee S, Choi T et al (2013) Hepatitis C virus NS4B inhibitor suppresses viral genome by disrupting NS4b’s dimerization/multimerization as well as its interaction with NS5A. Virus Genes 47:395–407PubMed

39.

Dufner-Beattie J, O’Guin A, O’Guin S et al (2014) Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother 58:3399–3410PubMedPubMedCentral

40.

Shotwell JB, Baskaran S, Chong P et al (2012) Imidazo[1,2-a]pyridines that directly interact with hepatitis C NS4B: initial preclinical characterization. ACS Med Chem Lett 3:565–569PubMedPubMedCentral

41.

Banka A, Catalano JG, Chong PY et al (2011) Preparation of piperazinyl antiviral agents. WO 2011041713

42.

Baskaran S, Maung J, Neitzel ML et al (2010) Preparation of imidazopyridine derivatives for treating viral infections. US 20100204265

43.

Baskaran S, Maung J, Neitzel M et al (2010) Preparation of imidazopyridine derivatives for treating viral infections. WO2010091409

44.

Miller JF, Chong PY, Shotwell JB et al (2014) Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem 57:2107–2120PubMed

45.

Pouliot JJ, Thomson M, Xie M et al (2015) Preclinical characterization and in vivo efficacy of GSK8853, a small-molecule inhibitor of the hepatitis C virus NS4B protein. Antimicrob Agents Chemother 59(10):6539–6550PubMedPubMedCentral

46.

Tai VW, Garrido D, Price DJ et al (2014) Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. Bioorg Med Chem Lett 24:2288–2294PubMed

47.

Wang NY, Xu Y, Zuo WQ et al (2015) Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. J Med Chem 58:2764–2778PubMed

48.

Chen G, Ren H, Turpoff A et al (2013) Discovery of N-(40-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication. Bioorg Med Chem Lett 23:3942–3946PubMed

49.

Zhang X, Zhang N, Chen G et al (2013) Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorg Med Chem Lett 23:3947–3953PubMed

50.

Zhang N, Zhang X, Zhu J et al (2014) Structure−activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. J Med Chem 57:2121–2135PubMed

51.

Graci JD, Jung SP, Pichardo J et al (2016) PTC725, an NS4B-targeting compound, inhibits a hepatitis C virus genotype 3 replicon, as predicted by genome sequence analysis and determined experimentally. Antimicrob Agents Chemother 60(12):7060–7066PubMedPubMedCentral

52.

Chen G, Ren H, Zhang N et al (2015) 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. Bioorg Med Chem Lett 25:781–786PubMed

53.

Zhang N, Turpoff A, Zhang X et al (2016) Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. Bioorg Med Chem Lett 26(2):594–601PubMed

54.

Kakarla R, Liu J, Naduthambi D et al (2014) Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. J Med Chem 57:2136–2160PubMed

55.

Sofia MJ, Kakarla R, Liu J et al (2012) Preparation of piperazine derivatives and their uses to treat viral infections, including hepatitis C. US20120202794A1

56.

Sofia MJ, Kakarla R, Liu J et al (2012) Preparation of pyrazine and imidazolidine derivatives and their uses to treat viral infections, including hepatitis C. WO2012103113A1

57.

Phillips B, Cai R, Delaney W et al (2014) Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J Med Chem 57:2161–2166PubMed

58.

Gleen JS, Cho NJ, Yang W (2010) Screening for inhibitors of HCV amphipathic helix (AH) function. WO2010/039192A2

Titel: Evolution of HCV NS4B Inhibitors
verfasst von: Giuseppe Manfroni
Rolando Cannalire
Verlag: Springer International Publishing
Buch: HCV: The Journey from Discovery to a Cure
Print ISBN: 978-3-030-28399-5

Electronic ISBN: 978-3-030-28400-8

Copyright-Jahr: 2019
DOI: https://doi.org/10.1007/7355_2018_46